FeesSafety
Pluang+

Ether (ETH) price drops 5.42% to $2,109 amid market shifts

Market News
09 Nov 2026, 08:57 WIB
Tokenpost
View Source
Bearish
Ether (ETH) price drops 5.42% to $2,109 amid market shifts

Ether (ETH) traded at $2,109.46 as of early Monday, marking a 5.42% decline over the past 24 hours. This drop reflects recent volatility in the digital asset markets, signaling cautious investor sentiment. Market watchers will be monitoring if this trend continues or stabilizes in the coming days.

Ether's trading at $2,109.46 as of Nov 09, 2026 13:51 WIB provides context for digital asset market activity. For readers following major cryptocurrencies on Pluang, 6 out of 50 priced assets rose while 43 fell. Notable movers include Litecoin at Rp905.725 with a 1-day change of -4.25% and a Pluang order activity split of 38% Sell / 62% Buy, Algorand at Rp1.647 down 4.08% with 73% Sell / 27% Buy, and Kusama at Rp55.878 down 3.99%.

More News

Oculis to host R&D Day showcasing late-stage pipeline for dry eye and neuro-ophthalmology treatments

Oculis to host R&D Day showcasing late-stage pipeline for dry eye and neuro-ophthalmology treatments

Oculis Holding AG announced an in-person and virtual R&D Day on December 8, 2026, to highlight key clinical developments in its late-stage pipeline, including Licaminlimab for dry eye disease and Privosegtor for neuro-ophthalmology and neurology. The...

Market News
Bullish
22 minutes ago
DNO ASA's offer for Capricorn Energy plc lapses, ending the acquisition attempt.

DNO ASA's offer for Capricorn Energy plc lapses, ending the acquisition attempt.

DNO ASA announced that its offer to acquire Capricorn Energy plc has lapsed as of November 9, 2026. This means the acquisition attempt will not proceed, impacting DNO's expansion plans in the oil and gas sector. Investors should monitor DNO's next st...

Market News
Neutral
22 minutes ago
Oculis announces R&D Day to showcase late-stage eye disease drug developments Licaminlimab and Privosegtor.

Oculis announces R&D Day to showcase late-stage eye disease drug developments Licaminlimab and Privosegtor.

Oculis Holding AG will hold a Research & Development Day on December 8, 2026, to present key clinical progress on its late-stage drug candidates Licaminlimab for dry eye disease and Privosegtor for neuro-ophthalmic conditions including optic neuritis...

Company Fundamentals
Bullish
22 minutes ago
Fraudulent robocall losses in North America to drop 33% by 2031 due to advanced fraud prevention.

Fraudulent robocall losses in North America to drop 33% by 2031 due to advanced fraud prevention.

Juniper Research forecasts that losses from fraudulent robocalls in North America will decrease by 33%, from $18.4 billion in 2026 to $12.3 billion in 2031. This decline is attributed to telecom operators adopting advanced fraud prevention technologi...

Market News
Bullish
22 minutes ago
Bitcoin ETFs see $1.28B outflows amid strong US jobs data and crypto regulation uncertainty

Bitcoin ETFs see $1.28B outflows amid strong US jobs data and crypto regulation uncertainty

US spot Bitcoin ETFs experienced $1.28 billion in net outflows during the week ending November 6, driven largely by BlackRock's iShares Bitcoin Trust withdrawals. This decline reflects weaker institutional demand and rising Treasury yields, compounde...

Market News
Bearish
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App